Program Objectives:

  1. Understand that not all obesity is the same: obesity is a multifactorial disease and understanding the underlying root cause is critical for optimal patient outcomes.

  2. Understand the role of the melanocortin-4 Receptor pathway (MC4R) impairment on syndromic and monogenic obesity and their effect on post-bariatric surgery outcomes.

  3. Evaluate data on setmelanotide, a precision therapy approved for chronic weight management for individuals with monogenic (POMC, PCSK1, and LEPR deficiencies) or syndromic obesity due to Bardet-Biedl Syndrome.